Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
PolleyMed, LLC - 726018 - 05/14/2026
The FDA issued a warning letter to PolleyMed, LLC for marketing its SaniiSwab™ nasal cleaning product as an unapproved new drug and for misbranding claims of FDA OTC approval. The agency’s review of the company’s website and social‑media content found statements that the product prevents infections, cites use in surgeries, and references specific pathogens, which classify it as a drug under the FD&C Act. Because no FDA application exists, the product’s interstate commerce is prohibited. PolleyMed must submit a corrective action plan within 15 business days.
Sourav K. Mishra, M.D. / All India Institute of Medical Sciences - 724881 - 04/29/2026
The FDA issued a warning letter to Dr. Sourav K. Mishra of AIIMS Bhubaneswar for serious violations in a bioequivalence study of doxorubicin hydrochloride liposome injection conducted for Qilu Pharmaceutical. The investigator administered the prohibited CYP3A4 inhibitor aprepitant to all...
The Future of Healthcare Screenings: The Power of Vocal Biomarkers
Vocal biomarkers—AI‑driven analysis of a 40‑second voice sample—are emerging as a rapid, non‑invasive screening tool for conditions ranging from mild cognitive impairment and Alzheimer’s to depression, anxiety, Parkinson’s and multiple sclerosis. Recent studies, including a Japanese trial of 1,461 seniors,...
SERB Pays €115 Million for Hansa Biopharma’s Idefirix Rights in Europe and MENA
SERB Pharmaceuticals agreed to buy exclusive rights to Hansa Biopharma's kidney‑transplant drug Idefirix across Europe and the MENA region for €115 million ($124 million). The deal includes an upfront €110 million payment and a €5 million contingent payment tied to EMA approval, positioning SERB...
Teen Temptations Beware: MAHA-Era FDA Gives Vapes, Tanning Beds a Boost
The FDA has authorized its first fruit‑flavored vaping products for adult use while signaling it will not prioritize enforcement against many unauthorized vapes and nicotine pouches still under review. At the same time, the agency withdrew a proposed ban on...
Sanofi's Efdoralprin Alfa Shows Triple Alpha‑1 Levels in Phase 2 AATD Emphysema Trial
Sanofi announced that its experimental drug efdoralprin alfa met the primary endpoint of its Phase 2 ElevAATe trial, delivering mean alpha‑1 antitrypsin trough levels more than three times higher than weekly plasma‑derived augmentation therapy. The result strengthens Sanofi’s rare‑disease portfolio and...
Turkey Rolls Out $110 Baby Bonus and Extended Parental Leave to Boost Fertility
President Recep Tayyip Erdogan announced a suite of pro‑birth measures, including a $110 cash bonus for first children, monthly stipends for larger families and an extension of maternity leave to 24 weeks. The policies come as Turkey’s total fertility rate...
Doximity Unbound
Doximity announced a rapid series of strategic moves, including renaming its DoxGPT chatbot to “Ask,” launching free e‑prescribing through a Surescripts partnership, and embedding its AI tools in Aledade’s large value‑based care network. These initiatives are packaged as a Clinical...
Wolters Kluwer Provides MDS Solution Medi-Span to The Christie NHS Foundation Trust
Wolters Kluwer Health has rolled out its Medi‑Span medication decision‑support platform at The Christie NHS Foundation Trust, the largest single‑site cancer centre in Europe. The solution is embedded within the Better Meds ePMA system, delivering real‑time allergy and drug‑interaction alerts directly into...
TAVR Day: What to Do and When to Do It
Transcatheter aortic valve replacement (TAVR) volumes have more than tripled over the past decade, driving a rapid expansion of the sonographer’s responsibilities. While most echocardiography education concentrates on post‑procedure follow‑up, the day‑of‑procedure imaging—baseline, intra‑procedural, and immediate post‑deployment—directly influences complication detection....
Why AI’s Healthcare Promise Is Stalling
Healthcare providers are amassing massive data streams, yet many struggle to turn that information into actionable insights. Health Catalyst’s Chief Product Officer Robbie Hughes argues that the AI promise stalls because organizations focus on new models instead of solid data...
A Match Made in Heaven: Has Your Blood Collection Tube Been Appropriately Validated with Your Assays?
Blood‑collection tubes are FDA‑cleared in‑vitro diagnostic devices, but their clearance does not confirm compatibility with every clinical assay or analyzer. CLSI guideline GP34‑A places the burden of full validation on manufacturers while laboratories are responsible for verification of tube‑assay combinations....
Bipartisan Bill Aims to Break Pharmacies Away From Health Insurers and PBMs
Congress is reintroducing the Patients Before Monopolies Act, a bipartisan bill that would require health insurers and pharmacy‑benefit managers (PBMs) to divest any pharmacies they own. The legislation is led in the Senate by Elizabeth Warren and Josh Hawley and...
Why some People Skip the Closest Pharmacy—And What that Means for Health Care Deserts
A new study from Cal Poly, published in Risk Analysis, reveals that Americans often skip the nearest pharmacy, choosing locations that match the socioeconomic character of their neighborhoods. While 98% of Los Angeles County residents live within 5 km of a pharmacy,...
FDA Approves First-Ever Gene Therapy For Deafness, Opening Door To New Era
The U.S. Food and Drug Administration has approved the world’s first gene therapy for deafness, targeting the OTOF mutation that blocks sound transmission in the inner ear. In a pivotal trial of 20 children and teens, 80% experienced improved hearing...
SERB to Pay Hansa €110M Upfront for EU Rights to Kidney Transplant Drug
SERB Pharmaceuticals will pay Hansa Biopharma €110 million (≈$119 million) upfront for exclusive rights to Idefirix across Europe, the Middle East and North Africa. The antibody‑cleaving enzyme, conditionally approved for highly sensitized kidney‑transplant patients, generated €18.7 million (≈$20 million) in 2025 sales but has...
3D Printing for All: Lessons From Hospitals That Built It From the Ground Up
Materialise’s recent forums highlighted how district hospitals are turning point‑of‑care 3D printing from a niche experiment into an operational service. At RUH Bath, a single printer was added to solve a logistics issue, then expanded to surgical planning and custom...
Novo Nordisk Goes All‑In on Global Wegovy Pill Launch
Novo Nordisk’s executive vice‑president for international operations, Emil Kongshøj Larsen, said the company will "go all in" on rolling out its Wegovy oral weight‑loss pill beyond the United States later this year. The move aims to capture new markets as...
AI Scribes: Hype vs Proven Efficiency in Healthcare
I used 𝑠𝑐𝑒𝑛𝑎𝑟𝑖𝑜 𝑎𝑛𝑎𝑙𝑦𝑠𝑖𝑠 to analyze the near future of AI scribes in their promise of replacing administration. Key driver: Growing evidence in studies Major uncertainty: Acceptance by medical professionals 𝐒𝐜𝐞𝐧𝐚𝐫𝐢𝐨 #𝟏. 𝐃𝐚𝐧𝐠𝐞𝐫𝐨𝐮𝐬 𝐇𝐲𝐩𝐞 (𝐇𝐢𝐠𝐡 𝐚𝐜𝐜𝐞𝐩𝐭𝐚𝐧𝐜𝐞 / 𝐋𝐨𝐰 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞) Clinicians adopt AI scribes enthusiastically...
PID: 58741 - Pediatric Endocrinology and Diabetes Specialists Charlotte
Advocate Health has opened a dedicated Pediatric Endocrinology and Diabetes clinic in Charlotte, North Carolina. The facility, located at 4501 Cameron Valley Parkway Suite 300, provides specialized hormone and diabetes care for children, with Spanish‑language support. It operates under program ID 7387...
Ovarian Cancer Clinical Trials: How Patient-Centered Design Can Improve Late-Line Study Enrollment
Genelux is advancing Olvi-Vec, an oncolytic immunotherapy, in late‑line ovarian cancer with a Phase III OnPrime trial that compares Olvi-Vec plus chemotherapy to physician’s choice. The Phase II VIRO‑15 study reported a 54% objective response rate, 11‑month median progression‑free survival...
Bayer’s Hyrnuo (Sevabertinib) Gains the US FDA Priority Review for 1L Treatment of HER2-Mutated NSCLC
Bayer’s Hyrnuo (sevabertinib) received FDA priority review for first‑line treatment of adults with locally advanced or metastatic non‑small cell lung cancer (NSCLC) harboring HER2 kinase‑domain activating mutations and no prior systemic therapy. The review follows promising interim data from Cohort F...
Stryker to Pay Up to $835 Million for Amplitude Vascular, Expanding Lithotripsy Portfolio
Stryker Corporation agreed to acquire Amplitude Vascular Systems for as much as $835 million, adding a next‑generation hydraulic intravascular lithotripsy platform to its vascular portfolio. The deal, announced on May 19, 2026, signals Stryker’s push to broaden options for treating calcified...
ACA Enrollment Falls 5‑6 Million, Prompting Insurers to Eye Further Premium Hikes
Health insurers are preparing for another wave of premium hikes after new data show ACA enrollment has slipped by 5‑6 million people. The drop, driven by the expiration of enhanced subsidies and rising deductibles, threatens market stability and could push more...
WHO Declares Congo-Uganda Ebola Outbreak a Global Health Emergency
The World Health Organization has declared the Ebola outbreak in the Democratic Republic of Congo and Uganda a public health emergency of international concern, citing over 300 suspected cases and more than 80 deaths. The rare Bundibugyo strain, for which...
The EU’s Rare Disease Lottery: Why Your Treatment Depends on Whether You Live in Ireland, Germany or Malta
Around 36 million Europeans—one in twelve—live with a rare disease, and treatments known as orphan drugs often carry steep price tags. After EMA approval, each member state must conduct its own health‑technology assessment (HTA) and decide reimbursement, creating a “lottery” of...
Hospital at Home: The New Model of Modern Care
Virtual hospitals, or "virtual wards," are delivering hospital‑level care to patients at home by using wearables, AI analytics and remote clinician oversight. Early trials show reduced readmissions and the ability to free up roughly three beds per day, while an...
Five Questions with Leonard M. Lopoo, Author of “Wanting Children: Family-Planning Policies and the Engineering of America’s Population”
Leonard M. Lopoo’s new book *Wanting Children* argues that U.S. family‑planning policy is skewed toward subsidizing contraception for low‑income Americans while ignoring infertility support, a legacy of early eugenicist policies. He introduces “wantedness” as a metric for population policy, emphasizing...
First Healthy Volunteers Receive TRIV-573 Doses in Triveni Bio’s Phase I Trial
Trivena Bio has dosed its first healthy volunteers in a Phase I trial of TRIV‑573, a half‑life‑extended bispecific antibody that simultaneously inhibits kallikreins 5/7 and blocks interleukin‑13. The dual‑target approach is designed to repair the skin barrier while curbing inflammation in moderate‑to‑severe...
Unsatisfactory Paps—Recommendations, Remedies
The third edition of the Bethesda System revises adequacy criteria for cervicovaginal Pap tests, setting specific cellularity thresholds—8,000‑12,000 squamous/metaplastic cells for conventional slides and 5,000 for liquid‑based preparations. Endocervical cells and normal endometrial cells no longer count toward these thresholds,...
New Smart Technology in Wearable Wristband May Detect Cardiac Arrest
A Dutch clinical trial (DETECT‑1b) tested a wrist‑worn photoplethysmography (PPG) device that automatically identifies cardiac arrest. Among 49 participants, the algorithm correctly flagged 92% of induced shockable events, achieving 100% detection for ventricular fibrillation and 90% for pulseless ventricular tachycardia....
Common Asthma Drug May Turn Off Tumor 'Switch' Tied to Immunotherapy Resistance
A Northwestern Medicine study published in Nature Cancer shows that blocking the cysteinyl leukotriene receptor 1 (CysLTR1) with the asthma drug montelukast can reverse immunotherapy resistance in several aggressive cancers. Experiments in mouse models and analyses of human tumor samples demonstrated...
The Operator Led Evolution in European Healthcare M&A: The Rise of Founder Bankers in HealthTech, MedTech, FemTech and Healthcare AI
European healthcare M&A is entering a structural inflection point as founder‑bankers—former entrepreneurs and clinicians—displace traditional bulge‑bracket banks for the majority of mid‑market HealthTech, MedTech, FemTech and AI deals. While large cross‑border mega‑transactions above €500 million still rely on Goldman Sachs or...
Africa CDC Declares Continental Emergency over Ebola Outbreak
Africa CDC has declared a Continental Public Health Emergency in response to the Ebola outbreak affecting the Democratic Republic of Congo and Uganda. The DRC has reported 131 deaths among 513 suspected cases, while Uganda has recorded a single fatality....
WHO Members Reject Proposal to Invite Taiwan to Participate in Annual Assembly
The World Health Assembly in Geneva voted to reject a proposal that would have invited Taiwan to participate as an observer, after China, backed by Pakistan, threatened to block any involvement. Delegates from Palau and other nations argued that excluding...
Survey on the EU Legal Framework for Health Data and Data Driven Health Technologies
The European Commission's DG CNECT, together with PwC EU Services, has launched a targeted survey running from 13 May to 22 May 2026. It seeks practical input from researchers, developers, regulators and other stakeholders on accessing and reusing health data while complying with...
Scaling Scientific R&D with AI Supercomputing Infrastructure — with Thomas Fuchs of Eli Lilly
In this episode, Thomas Fuchs, Chief AI Officer at Eli Lilly, explains how the company is building an AI‑ready supercomputing platform—based on NVIDIA’s DGX SuperPod B300 architecture—to accelerate drug discovery, development, and manufacturing. He highlights that the massive compute power lets...
Vaccine Experts Debate Options to Combat Outbreak of Unusual Ebola Strain
The World Health Organization convened a closed meeting of vaccine experts after the Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo was declared a public‑health emergency. The outbreak has produced roughly 500 suspected cases and more than 130...
Government Launches Major Overhaul of Mental Health Care with Focus on Prevention
The UK government unveiled a "once‑in‑a‑generation" mental health strategy that shifts emphasis from crisis intervention to prevention and early support. The plan allocates £473 million (≈$600 million) over four years for emergency departments, community services and youth hubs, while NHS mental‑health spending...
Saving the NDIS or Shrinking It? History Has a Warning for Mark Butler
Health Minister Mark Butler tabled the National Disability Insurance Scheme Amendment (Securing the NDIS for Future Generations) Bill on May 14, arguing it is essential to shield the program from mounting fiscal strain. The legislation seeks to tighten eligibility, introduce...
Viewpoint: ‘Crisis of Public Trust’: Autism Support Community Shocked RFK Continues to Peddle False Claims About the Danger of Vaccines
A newly released report urges Congress to hold oversight hearings and consider impeachment of officials such as Robert F. Kennedy Jr. for perpetuating vaccine misinformation. The report highlights a federal push to tie autism to prenatal acetaminophen use and the replacement of the...
Advanced Therapy: How Indonesia Can Escape the Middle-Income Trap
Indonesia stands at a crossroads as chronic disease rates climb and the global biopharma market expands rapidly. Advanced therapy medicinal products—gene, cell and RNA‑based treatments—are moving from futuristic concepts to strategic necessities, with more than 4,000 pipelines and roughly 150...
Maternity Staff Take Legal Action over ‘Hazardous’ Exposure to Nitrous Oxide
More than 100 maternity staff at Basildon Hospital in Essex have filed legal claims after being exposed to hazardous levels of nitrous oxide (Entonox) between 2018 and 2023. An internal report found gas concentrations up to 30 times the legal...
Southland Hospital Upgrades Diagnostic Imaging with New Fluoroscopy System
Southland Hospital in New Zealand has installed a new fluoroscopy system costing about S$994,000 (≈ $735,000 USD). The equipment delivers real‑time imaging at lower radiation levels and doubles as a general X‑ray suite, supporting procedures such as PICC line insertions. By expanding imaging...
Queensland Invests A$11.2 Million To Expand Clinical Trials Capacity And Create Biomedical Jobs
The Queensland Government is committing A$11.2 million (about $7.4 million USD) to expand Clinical Trials Group’s operations, establishing a new Phase 1 clinical trials facility in Brisbane. Backed by the A$180.6 million (≈$119 million USD) Sovereign Industry Development Fund, the project will feature over 40...
New Therapies Could Help Type 1 Diabetes Care Move Beyond Insulin Alone
A recent review in The Journal of Clinical Investigation outlines emerging disease-modifying therapies for type 1 diabetes that aim to preserve beta‑cell function alongside insulin. The anti‑CD3 antibody teplizumab showed a single 14‑day course can postpone clinical onset by up to...
CMS Deploys WISeR AI Initiative to Trim Wasteful Medicare Services
The Centers for Medicare & Medicaid Services has launched the Wasteful and Inappropriate Service Reduction (WISeR) Initiative, an AI‑driven utilization review model that will operate in Arizona, New Jersey, Ohio, Oklahoma, Texas and Washington. The program inserts machine‑learning checks into...
Maryland Board Caps Ozempic at $274 per Month, Second State Drug‑Cost Limit
The Maryland Prescription Drug Affordability Board voted to limit what state and local government health plans pay for Novo Nordisk’s Ozempic to $274 per month, effective January 2027. The decision follows an April cap on Jardiance and signals a growing...
VERTANICAL’s VER‑01 Gets FDA Breakthrough Therapy Designation for Chronic Low‑Back Pain
VERTANICAL announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to its oral pain drug VER‑01 for chronic low‑back pain. The designation speeds development and underscores the drug’s potential to address a massive unmet need for...
Testosterone Shots: SubQ or IM?
A 2022 head‑to‑head trial of 234 hypogonadal men compared weekly intramuscular testosterone cypionate with subcutaneous testosterone enanthate. Both routes achieved equivalent total testosterone levels, but the subcutaneous group showed significantly lower post‑therapy estradiol and hematocrit. The flatter absorption curve of...